Francesco Morrone
Research Subjects
Francesco Morrone has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Casati
U.O. Pediatria e Neonatologia, Dipartimento Materno Infantile, ASL Verbania Cusio Ossola, 28921 Verbania, Italy
1 shared publication - Alessandra Magenta
National Research Council of Italy (CNR), Institute of Translational Pharmacology (IFT), Rome, Italy
1 shared publication - Andrea Alba
Dipartimento di Salute della Donna e del Bambino, Azienda Ospedaliera Universitaria Padova, 35128 Padova, Italy
1 shared publication - Antonietta Distilo
UO di Pediatria e Nido di Paola/Cetraro, Dipartimento Materno Infantile, Spoke Hospital of Cetraro, Azienda Sanitaria Provinciale (ASP) Cosenza, 87022 Cosenza, Italy
1 shared publication - Antonino Di Toro
UO Terapia Intensiva Neonatale e Neonatologia, Dipartimento Area Critica, AORN Santobono Pausilipon, 80129 Naples, Italy
1 shared publication - Camilla Selvatico
SC Pediatria e DEA Pediatrico, AOU SS Antonio e Biagio e C. Arrigo, 15121 Alessandria, Italy
1 shared publication
Latest Publications
- Open Access
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8329
MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer
Cardio-oncology explores the complex interplay between cancer biology and cardiovascular health, particularly the cardiotoxic effects of cancer therapies. Both microRNAs (miRNAs) and alarmins have emerged as key molecular mediators linking tumor progression and cardiac stress, representing promising biomarkers and therapeutic targets. In skin and breast cancer, specific miRNAs, including miR-21, miR-155, miR-34a, and the miR-200 family, regulate tumor proliferation, invasion, metastasis, and therapy resistance. Alarmins such as NPM, HMGB1, HSPs, IL-33, and S100 proteins modulate inflammatory signaling, oxidative stress, and tissue remodeling, contributing to both tumor progression and cardiomyocyte dysfunction. These molecules are also implicated in chemotherapy- and targeted therapy-induced cardiotoxicity, including apoptosis, fibrosis, and impaired cardiac function. This review highlights the dual role of miRNAs and alarmins in tumor biology and cardiovascular toxicity, emphasizing their potential as circulating biomarkers for early detection and monitoring. Therapeutic strategies targeting this axis—including miRNA mimics/inhibitors and alarmin modulators—may provide synergistic benefits by reducing cardiotoxicity while suppressing tumor growth. Understanding miRNA–alarmin relationships, including direct interactions such as the NPM/miR-200c axis, as well as their broader regulatory networks in cardio-oncology, offers novel avenues for precision medicine, enabling integrated approaches to monitor, prevent, and treat therapy-related cardiac complications in patients with skin and breast cancers.
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8329
Open AccessMicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer
Cardio-oncology explores the complex interplay between cancer biology and cardiovascular health, particularly the cardiotoxic effects of cancer therapies. Both microRNAs (miRNAs) and alarmins have emerged as key molecular mediators linking tumor progression and cardiac stress, representing promising biomarkers and therapeutic targets. In skin and breast cancer, specific miRNAs, including miR-21, miR-155, miR-34a, and the miR-200 family, regulate tumor proliferation, invasion, metastasis, and therapy resistance. Alarmins such as NPM, HMGB1, HSPs, IL-33, and S100 proteins modulate inflammatory signaling, oxidative stress, and tissue remodeling, contributing to both tumor progression and cardiomyocyte dysfunction. These molecules are also implicated in chemotherapy- and targeted therapy-induced cardiotoxicity, including apoptosis, fibrosis, and impaired cardiac function. This review highlights the dual role of miRNAs and alarmins in tumor biology and cardiovascular toxicity, emphasizing their potential as circulating biomarkers for early detection and monitoring. Therapeutic strategies targeting this axis—including miRNA mimics/inhibitors and alarmin modulators—may provide synergistic benefits by reducing cardiotoxicity while suppressing tumor growth. Understanding miRNA–alarmin relationships, including direct interactions such as the NPM/miR-200c axis, as well as their broader regulatory networks in cardio-oncology, offers novel avenues for precision medicine, enabling integrated approaches to monitor, prevent, and treat therapy-related cardiac complications in patients with skin and breast cancers.
- Open Access
Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the epidemiology of lower respiratory tract infection (LRTI)-related hospitalizations in infants younger than 2 years during the first RSV season following the introduction of nirsevimab prophylaxis. A total of 401 hospitalizations were reported, with 40.4% being in children with previous prophylaxis with nirsevimab. Respiratory syncytial virus was the most frequently identified pathogen (47.5%), followed by rhinovirus/enterovirus (20.2%) and human metapneumovirus (hMPV; 6.9%). In multivariable analyses adjusted for age, sex, and month of diagnosis, prior nirsevimab immunization was associated with a significantly reduced likelihood of RSV-related hospitalization (adjusted odds ratio [aOR], 0.259; 95% CI, 0.157–0.427), corresponding to an estimated effectiveness of 74.1% (95% CI, 57.3–84.3). Conversely, nirsevimab-immunized infants showed increased odds of hospitalization due to hMPV (aOR, 2.490; 95% CI, 1.019–6.085) and rhinovirus/enterovirus (aOR, 2.573; 95% CI, 1.424–4.650). Lower respiratory tract infections associated with hMPV predominantly occurred outside the typical RSV season, being associated with moderate-to-severe clinical presentations. These findings confirm the real-world effectiveness of nirsevimab against RSV hospitalizations, also highlighting the need for the continued surveillance of non-RSV respiratory pathogens in the context of universal RSV immunoprophylaxis.
Open AccessDid Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the epidemiology of lower respiratory tract infection (LRTI)-related hospitalizations in infants younger than 2 years during the first RSV season following the introduction of nirsevimab prophylaxis. A total of 401 hospitalizations were reported, with 40.4% being in children with previous prophylaxis with nirsevimab. Respiratory syncytial virus was the most frequently identified pathogen (47.5%), followed by rhinovirus/enterovirus (20.2%) and human metapneumovirus (hMPV; 6.9%). In multivariable analyses adjusted for age, sex, and month of diagnosis, prior nirsevimab immunization was associated with a significantly reduced likelihood of RSV-related hospitalization (adjusted odds ratio [aOR], 0.259; 95% CI, 0.157–0.427), corresponding to an estimated effectiveness of 74.1% (95% CI, 57.3–84.3). Conversely, nirsevimab-immunized infants showed increased odds of hospitalization due to hMPV (aOR, 2.490; 95% CI, 1.019–6.085) and rhinovirus/enterovirus (aOR, 2.573; 95% CI, 1.424–4.650). Lower respiratory tract infections associated with hMPV predominantly occurred outside the typical RSV season, being associated with moderate-to-severe clinical presentations. These findings confirm the real-world effectiveness of nirsevimab against RSV hospitalizations, also highlighting the need for the continued surveillance of non-RSV respiratory pathogens in the context of universal RSV immunoprophylaxis.